


Cell Line Designation MM370
CellBank Catalogue No. CBA-1348
Lot Number 13480310S
Total Cell Number 2.1 x 10⁶ cells
Expected Cell Viability 80%

Brief Description Melanoma; from metastatic site - lymph node
Organism Human (*Homo Sapiens*)
Strain
Tissue Skin
Growth Properties Adherent
Morphology Epithelial

Image



Growth Medium RPMI 1640 (with 2mM L-Glutamine+ 25mM HEPES) +10% FBS
Subcultivation Ratio Optimal split ratio 1:8 (seeding density 0.6 x10⁴ cells/cm²).
 Harvest the cells using 0.05% Trypsin/EDTA at 37°C for 5 min.
 PC-2
Biosafety Level This cell line is sent with the condition that you are responsible for its safe storage, handling and use. CellBank Australia is not liable for damages or injuries resulting from receipt and/or use of a CellBank culture.
Use Restrictions These cells are distributed for research purposes only - refer to the Material Transfer Agreement (MTA).

<p>Safety Precaution</p>	<p>CellBank Australia highly recommends that protective gloves and clothing always be used and a full-face mask always be worn when handling frozen vials. It is important to note that some vials leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vessel exploding or blowing off its cap with dangerous force creating flying debris.</p>
<p>Handling Procedure for Frozen Cells</p>	<p>To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. Remove protective cryoflex layer prior to thaw. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapour phase and not at -80°C. Storage at -80°C will result in loss of viability.</p>
<p>Establishing and Maintaining your Culture Cryoprotectant Medium</p>	<p>Cells incubated at 37°C with 5% CO₂. Refer to Technical & Customer Service Information pamphlet. 10% DMSO + 90% FCS</p>
<p>Additional Information</p>	<p>Mutations: Homozygous deletion CDNK2A V599E mutations BRAF</p>
<p>Depositor</p>	<p>Peter Parsons - Queensland Institute of Medical Research, Australia</p>
<p>References</p>	<p>Maynard, K., and P.G. Parsons Cross-sensitivity to methylating agents, hydroxyurea and methotrexate in human tumour cells of the Mer- phenotype. Cancer Research 46:5009-5013, 1986</p>
<p>CellBank Warranty</p>	<p>While CellBank Australia uses reasonable efforts to include accurate and up-to date information on this product sheet, CellBank Australia makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. CellBank Australia does not warrant that such information has been confirmed to be accurate.</p>
<p>Disclaimers</p>	<p>This product is sent with the condition that you are responsible for its safe storage, handling, and use. CellBank Australia is not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to insure authenticity and reliability of strains on deposit, CellBank Australia is not liable for damages arising from the misidentification or misrepresentation of cultures.</p> <p>Please refer to the MTA for further details regarding the use of this product. The MTA is also available on our Web site at www.cellbankaustralia.com</p>